The first conference of Production-Study-Research platform for aptamer-based innovative drug discovery and development (co-organized by Qingfeng Medical Investment Group &  Institute for Advancing Translational Medicine in Bone & Joint Diseases (TMBJ), Hong Kong Baptist University) was held in Shenzhen.

At the conference, Dr. Xiaojuan He from TMBJ made a progress report about the recent development of the TMPC-01 (the first aptamer-based innovative drug). The results from the in vitro studies are promising, which prompt us to continue the research on toxicity and pharmacodynamics in a rat model to gain the in vivo evidence to support drug registration. Ms. Xiaoling Yang (Vice General Manager of Qingfeng Medical Investment Group) congratulated to the previous achievement of TMBJ and promised to provide more support for this institute and collaborative platform. At the end of the conference, the attendants made a productive discussion and a detailed schedule for further research on this project.

The team members from TMBJ and Qingfeng Medical Investment Group under discussion